Aims: To examine whether prenatal exposure to opioid agonist medication is associated with visual selective attention and general attention problems in early childhood. Method: Twenty-two children (mean age = 52.17 months, SD = 1.81) prenatally exposed to methadone, 9 children (mean age = 52.41 months, SD = 1.42) prenatally exposed to buprenorphine and 25 nonexposed comparison children (mean age = 51.44 months, SD = 1.31) were tested. Visual selective attention was measured with a Tobii 1750 Eye Tracker using a spatial negative priming paradigm. Attention problems were measured using the Child Behavior Checklist. Results: The comparison group demonstrated a larger spatial negative priming effect (mean = 23.50, SD = 45.50) than the exposed group [mean = -6.84, SD = 86.39, F(1,50) = 5.91, p = 0.019, η2 = 0.11]. No difference in reported attention problems was found [F(1,51) = 1.63, p = 0.21, η2 = 0.03]. Neonatal abstinence syndrome and prenatal exposure to marijuana were found to predict slower saccade latencies in the exposed group (b = 54.55, SE = 23.56, p = 0.03 and b = 88.86, SE = 32.07, p = 0.01, respectively). Conclusion: Although exposed children did not appear to have attention deficits in daily life, lower performance on the SNP task indicates subtle alteration in the attention system.

Keywords:
Prenatal exposure, Cognitive development, Visual attention, Methadone, Buprenorphine, Opioid maintenance therapy, Children, Child development
1.
Jones HE, Heil SH, Baewert A, Arria AM, Kaltenbach K, Martin PR, et al: Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction 2012;107:5-27.
2.
Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al: Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010;363:2320-2331.
3.
Jansson LM, Velez M: Neonatal abstinence syndrome. Curr Opin Pediatr 2012;24:252.
4.
Finnegan LP: Women, pregnancy and methadone. Heroin Add Rel Clin Probl 2000;2: 1-8.
5.
Kandall SR, Albin S, Lowinson J, Berle B, Eidelman AI, Gartner LM: Differential effects of maternal heroin and methadone use on birthweight. Pediatrics 1976;58:681-685.
6.
Farid W, Dunlop S, Tait R, Hulse G: The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr Neuropharmacol 2008;6:125.
7.
Konijnenberg C, Melinder A: Prenatal exposure to methadone and buprenorphine: a review of the potential effects on cognitive development. Child Neuropsychol 2011;17:495-519.
8.
Dettmar PW, Cowan A, Walter DS: A comparison of the neurochemicals effects of buprenorphine with those of morphine and haloperidol in rats. Eur J Pharmacol 1981;69:147-153.
9.
McGinty J, Ford D: Effects of prenatal methadone on rat brain catecholamines. Dev Neurosci 1980;3:224-234.
10.
Robinson SE, Maher JR, Wallace MJ, Kunko PM: Perinatal methadone exposure affects dopamine, norepinephrine, and serotonin in the weanling rat. Neurotoxicol Teratol 1997;19:295-303.
11.
Robbins T: Chemical neuromodulation of frontal-executive functions in humans and other animals. Exp Brain Res 2000;133:130-138.
12.
Vanderhasselt MA, De Raedt R, Baeken C, Leyman L, D'haenen H: The influence of rTMS over the left dorsolateral prefrontal cortex on Stroop task performance. Exp Brain Res 2006;169:279-282.
13.
Robinson SE: Effects of perinatal buprenorphine and methadone exposures on striatal cholinergic ontogeny. Neurotoxicol Teratol 2002;24:137-142.
14.
Himmelheber AM, Sarter M, Bruno JP: Increases in cortical acetylcholine release during sustained attention performance in rats. Brain Res Cogn Brain Res 2000;9:313-325.
15.
Marcus J, Hans SL, Jeremy RJ: A longitudinal study of offspring born to methadone-maintained women. III. Effects of multiple risk factors on development at 4, 8, and 12 months. Am J Drug Alcohol Ab 1984;10:195-207.
16.
Salo S, Politi J, Tupola S, Biringen Z, Kalland M, Halmesmäki E, et al: Early development of opioid-exposed infants born to mothers in buprenorphine-replacement therapy. J Reprod Infant Psyc 2010;28:161-179.
17.
Velez ML, Jansson LM, Schroeder J, Williams E: Prenatal methadone exposure and neonatal neurobehavioral functioning. Pediatr Res 2009;66:704-709.
18.
Wilson GS, Desmond MM, Wait RB: Follow-up of methadone-treated and untreated narcotic-dependent women and their infants: health, developmental, and social implications. J Pediatr 1981;98:716-722.
19.
Gaymard B: Cortical and sub-cortical control of saccades and clinical application. Rev Neurol 2012;168:734-740.
20.
Kelly SP, Lalor EC, Finucane C, McDarby G, Reilly RB: Visual spatial attention control in an independent brain-computer interface. IEEE Trans Biomed Eng 2005;52:1588-1596.
21.
Chelazzi L, Della Libera C, Sani I, Santandrea E: Neural basis of visual selective attention. Wiley Interdiscip Rev Cogn Sci 2011;2:392-407.
22.
Konijnenberg C, Melinder A: Neurodevelopmental investigation of the mirror neurone system in children of women receiving opioid maintenance therapy during pregnancy. Addiction 2013;108:154-160.
23.
Melinder A, Konijnenberg C, Sarfi M: Deviant smooth pursuit in preschool children prenatally exposed to methadone or buprenorphine and tobacco affects integrative visuomotor capabilities. Addiction 2013;108:2175-2182.
24.
Van Donkelaar P, Drew AS: The allocation of attention during smooth pursuit eye movements. Prog Brain Res 2002;140:267-277.
25.
Friedman L, Jesberger J, Siever L, Thompson P, Mohs R, Meltzer H: Smooth pursuit performance in patients with affective disorders or schizophrenia and normal controls: analysis with specific oculomotor measures, RMS error and qualitative ratings. Psychol Med 1995;25:387-404.
26.
Jacobsen LK, Hong WL, Hommer DW, Hamburger SD, Castellanos FX, Frazier JA, et al: Smooth pursuit eye movements in childhood-onset schizophrenia: comparison with attention-deficit hyperactivity disorder and normal controls. Biol Psychiatry 1996;40:1144-1154.
27.
Maruff P, Hay D, Malone V, Currie J: Asymmetries in the covert orienting of visual spatial attention in schizophrenia. Neuropsychologia 1995;33:1205-1223.
28.
McDonald S, Bennett K, Chambers H, Castiello U: Covert orienting and focusing of attention in children with attention deficit hyperactivity disorder. Neuropsychologia 1999;37:345-356.
29.
Bakstad B, Sarfi M, Welle-Strand GK, Ravndal E: Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. Eur Addict Res 2009;15:128-134.
30.
Amso D, Johnson SP: Selection and inhibition in infancy: evidence from the spatial negative priming paradigm. Cognition 2005;95:B27-B36.
31.
Amso D, Johnson SP: Development of visual selection in 3- to 9-month-olds: evidence from saccades to previously ignore locations. Infancy 2008;13:675-686.
32.
Tipper SP, Weaver B, Milliken B: Spatial negative priming without mismatching: comment on Park and Kanwisher (1994). J Exp Psychol Hum Percept Perform 1995;21:1220-1229.
33.
Achenbach T: Manual for the CBCL/4-18 and 1991 Profile. Burlington, University of Vermont, Department of Psychiatry, 1991.
34.
Cohen J: Statistical Power Analysis for the Behavioral Sciences, ed 2. Hillsdale, Lawrence Erlbaum, 1988.
35.
Mayes LC, Grillon C, Granger R, Schottenfeld R: Regulation of arousal and attention in preschool children exposed to cocaine prenatally. Ann NY Acad Sci 1998;846:126-143.
36.
Ornoy A, Michailevskaya V, Lukashov I, Bar-Hamburger R, Harel S: The developmental outcome of children born to heroin-dependent mothers, raised at home or adopted. Child Abuse Negl 1996;20:385-396.
37.
Brown RT, Coles CD, Smith IE, Platzman KA, Silverstein J, Erickson S, et al: Effects of prenatal alcohol exposure at school age. II. Attention and behavior. Neurotoxicol Teratol 1991;13:369-376.
38.
Biederman J, Faraone SV, Monuteaux MC: Differential effect of environmental adversity by gender: Rutter's index of adversity in a group of boys and girls with and without ADHD. Am J Psychiatry 2002;159:1556-1562.
39.
Rietveld MJH, Hudziak JJ, Bartels M, Beijsterveldt CEM, Boomsma DI: Heritability of attention problems in children: longitudinal results from a study of twins, age 3-12. J Child Psychol Psyc 2004;45:577-588.
40.
Gunnar MR: Quality of early care and buffering of neuroendocrine stress reactions: potential effects on the developing brain. Preventive Medicine 1998;27:208-211.
41.
Chevalier N, Blaye A, Dufau S, Lucenet J: What visual information do children and adults consider while switching between tasks? Eye-tracking investigation of cognitive flexibility development. Dev Psychol 2010;46:955-972.
42.
Thibaut JP, French R, Missault A, Gérard Y, Glady Y: In the Eyes of the Beholder: What Eye-Tracking Reveals About Analogy-Making Strategies in Children and Adults. Proceed Thirty-Third Annu Meet Cogn Sci Soc 2011, pp 453-458.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.